LivaNova wins FDA approval for aura6000 sleep apnea implant

LivaNova has secured U.S. FDA premarket approval for its aura6000 system, an implantable hypoglossal nerve stimulation device for adults with moderate to severe obstructive sleep apnea. The approval, dated March 18, 2026, covers patients with an apnea-hypopnea index of 15 to 65 who have failed, can’t tolerate, or aren’t eligible for standard therapies including positive airway pressure, oral appliances, or pharmacotherapy. FDA records show the device was approved under PMA P250013, and LivaNova has positioned aura6000 as a differentiated proximal hypoglossal nerve stimulation platform supported by its OSPREY trial data. (accessdata.fda.gov)

Why it matters: For veterinary professionals, this is a human medtech and regulation story rather than a direct animal health development, but it’s still worth watching because it highlights how implantable neurostimulation platforms are expanding into chronic conditions well beyond traditional uses, including airway, sleep, and even cognitive indications. That broader trend was underscored separately by FDA’s Breakthrough Device designation for Nia Therapeutics’ fully implantable closed-loop Smart Neurostimulation System for episodic memory loss after traumatic brain injury. The approval also adds competition in the sleep apnea device market, where Inspire has been the best-known FDA-approved upper airway stimulation option. Notably, FDA’s posted indication for aura6000 does not include the complete concentric collapse restriction that appears in Inspire’s labeling, which could matter for referral patterns, payer discussions, and broader market adoption if LivaNova converts approval into commercial uptake. (accessdata.fda.gov)

What to watch: Next comes commercialization timing, coverage and reimbursement decisions, and whether LivaNova’s planned U.S. launch in 2027 holds. More broadly, the aura6000 decision fits a wider FDA pattern of supporting implantable neuromodulation platforms, including closed-loop systems now being advanced for memory loss and other hard-to-treat conditions. (medicaldevice-network.com)